Juno, Kite Pharma Aim for two thousand seventeen CAR-T Therapy Approvals

A fresh treatment to immunotherapy that engineers patients’ immune cells to recognize and attack tumor cells resumes to build up speed: Juno Therapeutics and Kite Pharma both intend to bring chimeric antigen receptor T-cell (CAR-T) therapies to market next year. Continue reading Juno, Kite Pharma Aim for two thousand seventeen CAR-T Therapy Approvals